Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemolizumab - Chugai Pharmaceutical

Next Previous
Drug Profile

Nemolizumab - Chugai Pharmaceutical

Alternative Names: Anti-IL-31-receptor-monoclonal-antibody - Chugai Pharmaceutical; CD-14152; CIM 331; IL-31RA monoclonal antibody - Chugai Pharmaceutical; M 5250; M 5250B; Mitchga; Nemluvio; Nemolizumab-ilto

Latest Information Update: 08 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Galderma; Maruho
  • Class Anti-inflammatories; Antipruritics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 31 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis; Prurigo nodularis; Pruritus
  • Phase II Scleroderma

Most Recent Events

  • 22 Jul 2025 Galderma plans a phase II trial for Pruritus in USA (SC) in July 2025 (NCT07074977)
  • 09 Jul 2025 Galderma plans a phase II trial for Systemic scleroderma (In adults, In the elderly, Treatment-experienced) in Europe, North America and South America (SC, Injection), in August 2025 , (NCT07047690)
  • 30 Jun 2025 Galderma plans a phase II trial for Pruritus in USA (SC) in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top